Changing Lifestyles Necessitate Change in Game Plan of Breast Cancer Therapeutics Providers
The changing lifestyles and the growing issue of obesity have heightened the risk of breast cancer amongst women in recent years. Statistics indicate that breast cancer has become the second largest cause of fatalities across the globe. Thus, the increasing number initiatives to raise awareness about this deadly disease and treat patients for this disease has boosted the global breast cancer therapeutics market. The increasing awareness amongst patients about the disease and improving accessibility to premium treatments has also augmented the sales of various drugs in this market. Effective research and development for new treatments to efficiently treat breast cancer is also expected to change the game for this market.
Transparency Market Research forecasts that the global breast cancer therapeutics market is expected to be worth US$16.21 bn by 2023 as compared to US$7.17 bn in 2014, surging at a CAGR of 8.4% between 2015 and 2023. The drastically changing reproductive patterns are also responsible for soaring revenue earnings of the breast cancer therapeutics market. The delayed childbearing age, reduced breastfeeding periods, intake of oral contraceptives, and resorting to hormonal therapies to solve other medical conditions is also contributing towards the growth of this market.
Higher Percentage of Survivors in North America Puts Region in the Lead
A study conducted by World Cancer Research Fund International (WCRF) stated that North America has the highest percentage of breast cancer survivors after diagnoses, while it is the lowest in the developing countries of Asia and Africa. However, breast cancer continues to be a serious health concern in South America, Africa, and Asia.
WRCF also states that North America has a high incidence of breast cancer, however, the breast cancer therapeutics market is progressing in this region due to supportive insurance schemes meted by the government. The overall North America breast cancer therapeutics market is expected to surge at 7.3% CAGR between 2015 and 2023 during the forecast period. The risks of post-treatment complications and relapse are the only two key factors hampering this regional market.
Accurate Diagnosis through HER2 Inhibitors Increases Preference for the Drug Class
Amongst the various drug classes, the HER2 inhibitors segment was the leading segment in 2014. During the forecast period, the HER2 inhibitors segment is expected to expand at a CAGR of 6.2% due to their ability to deliver accurate diagnostics. HER2 inhibitors are used in case of metastatic breast cancer (MBC) patients who have undergone a minimum of two chemotherapeutic schedules of taxane and anthracycline. All of these factors are expected to raise the market opportunity of the HER2 inhibitors segment to a significant amount by the end of forecast period.
The key players operating in the global breast cancer therapeutics market are GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca plc, Pfizer, Inc., F. Hoffmann-La Roche Ltd., Puma Biotechnology, Novartis International AG, and Sanofi S.A. Companies are focusing on research and development to launch new products along with acquiring small companies to improve the existing line of products. However, these companies are governed by strict regulatory framework, which often causes delay in launching products.
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
2 Executive Summary
2.1 Global Breast Cancer Therapeutics: Market Snapshot
2.2 Global Breast Cancer Therapeutics Market Share, by Geography, 2014 & 2023(Value %)
2.3 Global Breast Cancer Therapeutics Market, by Drug Class, 2014 & 2023 (Value %)
3 Global Breast Cancer Therapeutics Market - Market Overview
3.1 Market Definition and Overview
3.2 Epidemiology & High Risk Groups
3.3 Diagnosis and Types of Breast Cancer
3.4 Other Breast Cancer Therapies
3.5 Market Dynamics
18.104.22.168 Higher Incidence Rate
22.214.171.124 Demographic Transition
126.96.36.199 Rising Prevalence Of Obesity
188.8.131.52 Diagnostic Screening Programs
184.108.40.206 Increase in Private Health Insurance Plans:
220.127.116.11 Generic Drugs: Substitute Branded Drugs
18.104.22.168 Intense Competition: Fall in Prices
22.214.171.124 Access barriers due to high drug costs
126.96.36.199 Absence of Social Health Insurance
188.8.131.52 Serious Side Effects of Breast Cancer Therapeutics
184.108.40.206 Countries Lacking Women Empowerment
220.127.116.11 Newer medication options
18.104.22.168 Potential Growth of Domestic Pharmaceutical Companies
22.214.171.124 Combination Drug Therapy
126.96.36.199 Technological Advancements and Robust Trends of Drug Approval
188.8.131.52 New Companion Diagnostics Models
184.108.40.206 Drug Therapy for Triple Negative (TNBC)
220.127.116.11 Approval for Multiple Indications (positive & negative types) HER2 breast cancer
3.7 Market Attractiveness Analysis– Breast Cancer Therapeutics Market, by Geography (2014) (%)
3.8 Competitive Landscape – Breast Cancer Therapeutics Market, by Key Players, 2014 (%)
4 Market Segmentation – By Drug Class
4.2 Global HER2 Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.2.1 Herceptin (Trastuzumab)
4.2.2 Tykerb (Lapatinib)
4.2.3 Perjeta (Pertuzumab)
4.2.4 Kadcyla (Ado-trastuzumab emtansine)
4.3 Global Mitotic Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.3.1 Halaven (Eribulin)
4.3.2 Taxotere (Docetaxel)
4.3.3 Ixempra (Ixabepilone)
4.4 Global Anti-metabolites Market Revenue, 2015–2023 (US$ Mn)
4.4.1 Gemzar (Gemcitabine)
4.5 Global Aromatase Inhibitors Market Revenue, 2015–2023 (US$ Mn)
4.5.1 Femara (Leterozole)
4.5.2 Aromasin (Exemestane)
4.5.3 Arimidex (Anastrozole)
4.5.4 Ibrance (Palbociclib)
4.5.5 Afinitor (Everolimus)
4.6 Global Hormone Receptor Market Revenue, 2015–2023 (US$ Mn)
5 Market Segmentation – By Geography
5.2 Global Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.3 North America Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4 Europe Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.4.4 Rest of Europe
5.5 Asia Pacific Breast Cancer Therapeutics Market Revenue, 2015–2023 (US$ Mn)
5.5.2 South Korea
5.5.3 Rest of Asia Pacific
5.6 Rest of the World
5.6.1 Latin America
18.104.22.168 Rest of Latin America
5.6.2 Middle East and Africa
7 Company Profiles
7.1 AstraZeneca plc
7.2 Eisai Co., Ltd.
7.3 Eli Lilly and Company
7.4 F. Hoffmann-La Roche Ltd.
7.5 GlaxoSmithKline plc
7.6 Novartis International AG
7.7 Pfizer, Inc.
7.8 Puma Biotechnology, Inc.
7.9 Sanofi S.A.
7.10 Teva Pharmaceutical Industries Ltd.
Global Breast Cancer Therapeutics Market: Overview
Changes in lifestyle and obesity are some of the key risk factors causing breast cancer. The incidence of the disease is more prevalent in women than in men, and is aggravated by the presence of several co-morbidity factors, with no clear causes. According to Breastcancer.org, a non-profit organization working on the diagnosis, treatment, and management of the disease, about one in eight women in the U.S. is likely to develop invasive breast cancer over the lifetime span. It is understood that hormone replacement therapy (HRT) occupied a significant role in bringing down the incidence rate among women in the U.S. since 2000.
The growing awareness of the prevalence of breast cancer and recent advances in targeted therapies have positively impacted the growth of the market. Constant efforts by researchers and clinicians in discovering new and better targets for cancer cell growth bode well for the market growth. The growing initiatives related to the development and marketing of next-generation diagnostic assays is expected to open new avenues for therapeutics for the breast cancer therapeutics market.
The report offers in-depth insights into the key market dynamics, recent technological advances in treatment therapies, emerging opportunities in various regions, and competitive landscape. The study takes a closer look at the scope of major drug classes, recent developments in targeted therapies in cancer, and the factors driving the major regional markets.
Global Breast Cancer Therapeutics Market: Trends and Opportunities
The growing incidence of breast cancer in women due to the presence of several risk factors and the growing prevalence of obesity due to unhealthy lifestyle modifications are some of the key factors driving the breast cancer therapeutics market. The indiscriminate intake of oral contraceptives and other estrogen-modifying drugs by women are considered to augment the risk factors, favorable impacting the growth of the market. The rapidly expanding geriatric populations in developing and developed nations has also catalyzed the growth of the market. The growing popularity of companion diagnostics among pharmaceutical companies is expected to expand the potential of targeted therapies in the treatment of this multifaceted disease.
Recent research and development activities related to the discovery of efficacious treatments in developed regions are expected to boost the market. In addition, the trend of several pharmaceutical and biotechnology companies making substantial investments in developing targeted therapies is expected to bode well in the coming years. Numerous regional players are developing generic drugs to address a large chunk of unmet demands of patients with breast cancer, which is expected to boost the breast cancer therapeutics market. The recent discovery of potential targets and the use of effector proteins as anticancer agents are expected to open up promising prospects over the forecast period.
Global Breast Cancer Therapeutics Market: Regional Outlook
Currently, North America is a prominent market for breast cancer therapeutics and the regional market occupies a substantial share. The prominence of the market share is driven by the presence of several favorable insurance schemes. The growing popularity of HER2 (from human epidermal growth factor receptor 2) to meet the demand for generic drugs is attributed to the patent of various biologic drugs in the region. This is expected to significantly boost the regional market over the forecast period. The incidence and prevalence of breast cancer is expected to support the stellar growth of the North America market for breast cancer therapeutics.
Global Breast Cancer Therapeutics Market: Companies mentioned in the report
Several players are actively focusing on research and development activities to launch new drug classes and therapies. They are also acquiring small regional companies to consolidate their product portfolio. Major players operating in the cancer therapeutics market include Sanofi S.A., Novartis, Puma Biotechnology, F. Hoffmann-La Roche Ltd., Pfizer, Inc., AstraZeneca plc, Eli Lilly and Company, and GlaxoSmithKline plc.
Major regions analyzed under this research report are:
- North America
- Asia Pacific
- The Middle East and Africa
- Latin America
This report gives you access to decisive data such as:
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for the coming years
Key highlights of this report
- Overview of key market forces propelling and restraining market growth
- Up-to-date analyses of market trends and technological improvements
- Pin-point analyses of market competition dynamics to offer you a competitive edge
- An analysis of strategies of major competitors
- An array of graphics and SWOT analysis of major industry segments
- Detailed analyses of industry trends
- A well-defined technological growth map with an impact-analysis
- Offers a clear understanding of the competitive landscape and key product segments